Accelerating Drug Development Through Integrated CDMO And CRO Partnership

If you're managing drug development across multiple vendors, you already know the problem: you end up as the de facto project integrator, chasing timelines between suppliers who have no visibility into each other's work. Thermo Fisher Scientific experts make the case that this is one of the most preventable sources of delay and cost in drug development, and the fix starts earlier than most teams think.

The core argument here is worth sitting with: don't optimize for your next milestone, optimize for the full journey. That means thinking about commercialization before you've finished Phase I, building scalable manufacturing processes with documented process parameters, and locking in raw material reliability before GMP scale becomes a pressure point.

Where integrated CDMO and CRO partnerships actually earn their keep is in clinical supply planning. Working with a connected CRO early, when dosage form, patient population, and packaging strategy are still being defined, compresses timelines and reduces rework downstream. The teams here describe cross-functional governance as the operational backbone that makes end-to-end connectivity real, not theoretical.

Access the full discussion to see how early planning decisions directly shape the speed and cost of your development program.